P2X3 inhibitor shows 75 percent reduction in chronic cough frequency

25 noviembre 2014

Results from a Phase 2 clinical trial have been published, demonstrating that a drug candidate — AF-219 — reduced daytime cough frequency by 75 percent compared to placebo in patients with treatment-refractory chronic cough. AF-219 is a selective, non-narcotic, orally administered P2X3 receptor antagonist targeting the mechanism by which certain nerve fibers become hyper-sensitized.